Rankings
▼
Calendar
SUPN Q4 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q4 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$144M
+42.9% YoY
Gross Profit
$125M
87.1% margin
Operating Income
$43M
30.0% margin
Net Income
$31M
21.4% margin
EPS (Diluted)
$0.57
QoQ Revenue Growth
-7.5%
Cash Flow
Operating Cash Flow
$32M
Free Cash Flow
$32M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$759M
Stockholders' Equity
$745M
Cash & Equivalents
$289M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$144M
$100M
+42.9%
Gross Profit
$125M
$96M
+29.8%
Operating Income
$43M
$41M
+5.3%
Net Income
$31M
$33M
-7.1%
Revenue Segments
Product
$141M
50%
Trokendi Xr
$79M
28%
APOKYN
$31M
11%
Oxtellar X R
$23M
8%
MYOBLOC
$4M
2%
XADAGO
$4M
1%
Royalty
$3M
1%
← FY 2020
All Quarters
Q1 2021 →